Breaking news

European Commission Poised to Issue New Guidance on AI Act Compliance

The European Commission is expected to release key guidelines by the end of the year to help thousands of organizations navigate the landmark artificial intelligence rules. The delay, now extended by six months, reflects rigorous deliberations aimed at refining the implementation strategy for the Code of Practice.

Refining The Regulatory Framework

A Commission spokesperson confirmed that discussions by the European AI Board are focusing on the timeline for implementing the Code of Practice associated with the AI Act’s Guidelines for Predictive Artificial Intelligence (GPAI) rules. The possibility of final guidance emerging by the end of 2025 underscores the Commission’s commitment to a methodical rollout.

Implications For Industry Leaders

The GPAI rules, which primarily target large language models such as OpenAI’s ChatGPT and comparable platforms from tech giants like Google and Mistral, are set to influence a broad spectrum of AI applications. Companies across different sectors will need to align with these new regulations to ensure compliance, a transformation that may dictate future technology investments and usage. For instance, organizations leveraging generative AI can expect significant shifts in operational compliance strategies as new guidelines take effect.

Revised Timelines And Strategic Considerations

The initial deadline of May 2 for the introduction of these compliance standards has now been pushed back, providing additional time for stakeholders to prepare for the changes ahead. This delay, although challenging for some, offers a strategic window for companies to review their AI use cases and update their compliance frameworks accordingly.

As the European Commission continues to engage with industry experts and key policymakers, businesses should monitor these developments closely to ensure a smooth transition under the evolving regulatory landscape.

EU Records €220.5 Billion Pharmaceutical Trade Surplus In 2025

The European Union secured a historic trade surplus in medicinal and pharmaceutical products in 2025, according to a report from Eurostat. Export figures reached €366.2 billion while imports totaled €145.7 billion, leading to a surplus of €220.5 billion.

Robust Growth In Exports And Imports

Exports increased by 16.0% from €315.7 billion in 2024. Imports rose by 21.0% from €120.4 billion over the same period. The data show continued expansion in trade volumes across the sector.

Leading National Performances

Ireland recorded the highest exports to non-EU countries at €93.8 billion. Germany and Belgium followed with €67.9 billion and €38.5 billion, respectively. Italy led imports at €27.5 billion, with Belgium and Germany also recording significant volumes.

Global Trade Partnerships

The United States was the largest destination for EU exports, accounting for 43.8% or €160.6 billion. Switzerland followed with 16.3% (€59.7 billion), while the United Kingdom accounted for 5.6% (€20.6 billion). On the import side, the United States supplied 41.2% of total imports (€60.1 billion), followed by Switzerland at 28.4% (€41.4 billion) and China at 9.0% (€13.1 billion).

Aretilaw firm
The Future Forbes Realty Global Properties
eCredo
Uol

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter